USD 7 Billion Worth of Pharmaceutical Lipids will be Sold by 2030

As per FMI – an ESOMAR-certified market research firm, the global pharmaceutical lipids market is expected to witness a CAGR of over 5% and surpass USD 7 Bn by 2030.

The pharmaceutical lipids market players are focusing on Lipid nanocarriers are being increasingly used in the form of drug delivery systems as they are reported to be less toxic and render better biocompatibility in comparison with polymeric nanoparticles. This factor is prompting market players to switch over to lipid-based formulations and the trend is expected to continue in the forecast period as well.

To remain ‘ahead’ of your competitors, request for a sample>>> https://www.futuremarketinsights.com/reports/sample/rep-gb-10983

Key Takeaways of Pharmaceutical Lipids Market Study

• Triglycerides held maximum value in the global pharmaceutical lipids market in 2019 due to ease of manufacturing and greater efficacy
• Conventional LBDDS (Lipid-based Drug Delivery Systems) contributes for close to 75% of the entire pharmaceutical lipids market revenue
• East Asia is expected to hold around 27% of market revenue in 2020
• Growing inclination towards biosimilars and generic drugs using lipid-based formulations to be one of the growth drivers

“Manufacturers are continuously focusing on enhancing product production capacity and product availability to propel the growth of global pharmaceutical lipids market”. – says FMI analyst.

It should be noted that making use of high temperature lipid when filtration is imperative could prove to be tough. The properties to be pondered about include headgroup species, hydrocarbon length, and unsaturation charge.

Assembling protein aggregates on platelets asks for negatively charged surface. If charge needs to be satisfied with system specificity, that charge could act as hindrance.

The more unsaturated the compound is, it easier it is to oxidize. This, in turn, results in shorter shelf life. That’s why synthetic lipid compounds last longer. The naturally contained lipids contain a significant amount of polyunsaturated fatty acids. So, future belongs to synthetic, or at least semi-synthetic lipids.

More often, single lipid species do not suffice, as far as physical properties required for a specific system are needed. In this case, it’s advisable to go for complex lipid mixture. Synthetic lipid blends are preferable, as reproducibility quotient is high.

Increasing Research Collaboration Merger & Acquisition – Imperative Strategy for Market Players

Pharmaceutical lipids market is largely consolidated thus manufacturers are focused on strengthening their sales network in the regional markets.

Manufacturers are focusing on acquisitions and mergers with smaller players — in order to strengthen the sales footprint, manufacturers are also signing long term supply agreements with the end users.

• For example, in 2015, Merck acquired Sigma Aldrich, a global player in the life science products

Get Access to Research Methodology Prepared by Experts>>> https://www.futuremarketinsights.com/ask-question/rep-gb-10983

What else is in the report?

Future market insights offer a unique perspective and actionable insights on pharmaceutical lipids market in its latest study, presenting historical demand assessment from 2015 – 2019 and projections from 2020–2030 based on product type (Triglycerides, Phospholipids, Sphingolipids, Cholesterol, Fatty Acids, and Others), by form (Liquid, Semi-solid, Solid), by source (Synthetic, Semi-synthetic and Natural) by application (Conventional Lipid-based Drug Delivery Systems (LBDDS), Self-Emulsifying Drug Delivery Systems (SEDDS), Self-Microemulsifying Drug Delivery Systems (SMEDDS), Liposomes, Solid Lipid Nanoparticles, Nanostructured Lipid Carriers, and Others) in seven key regions.